A61K35/62

Ascaroside treatment of eosinophilic esophagitis

A method of preventing or treating eosinophilic esophagitis (EoE) comprising administering a composition comprising ascr#7 is described.

Ascaroside treatment of eosinophilic esophagitis

A method of preventing or treating eosinophilic esophagitis (EoE) comprising administering a composition comprising ascr#7 is described.

COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME

A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.

COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME

A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.

Compositions and methods for characterizing a microbiome

A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.

Compositions and methods for characterizing a microbiome

A system is provided comprising a plurality of C. elegans cultures, where each culture comprises a transgenic C. elegans strain that models a mammalian disease or condition. Methods of using a system, e.g., for characterizing microbial strains of a mammalian microbiome and determining whether such microbial strains affect a mammalian disease or disorder.

MUTANT PORE

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.

MUTANT PORE

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using the mutant forms of lysenin.

PRODUCTION METHOD OF NASAL DROP COMPOSITION, AND NASAL DROP COMPOSITION
20210322487 · 2021-10-21 · ·

Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and

PRODUCTION METHOD OF NASAL DROP COMPOSITION, AND NASAL DROP COMPOSITION
20210322487 · 2021-10-21 · ·

Provided are: a method for producing a nasal drop composition suitable for treatment or prevention of a disease or symptom in the nasal cavities; and a nasal drop composition produced by the production method. The nasal drop composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the nasal drop composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and